Jefferies analyst Michael Yee believes the FDA's communication to Esperion Therapeutic that it does not plan to host an advisory panel removes a bear argument. The analyst is surprised by the news and keeps a Buy rating on the shares with an $85 price target.
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Altamira Therapeutics... To see the rest of the story go to thefly.com. See Story Here
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Altamira Therapeutics... To see the rest of the story go to thefly.com. See Story Here